The challenging diagnosis of cardiac amyloidosis

A Gavin, CJ Coats, W Wallace, AD Flapan

ABSTRACT Cardiac amyloidosis is a rare condition. Early diagnosis allows for more effective treatment with subsequent improvements in patient quality of life and survival. There is, however, often a significant delay between the initial presentation with symptoms and the eventual diagnosis. We present seven individual cases presenting to our centre over a 12-month period for whom the final diagnosis was cardiac amyloidosis. We look at the difficulties encountered and alternative diagnoses that were considered before the eventual diagnosis of cardiac amyloidosis was made. We discuss the apparent discrepancies often encountered between the clinical signs and the results of various investigations. We review the various tests that can help the clinician to make the diagnosis in patients with suspected cardiac amyloidosis and look at the treatment options. Finally, we conclude that careful evaluation of the clinical status in the context of all available results should allow early diagnosis and treatment, thereby improving long-term prognosis.

INTRODUCTION

Amyloidosis is a disease caused by the infiltration of various organs with insoluble eosinophilic protein fibrils. These extracellular amyloid proteins are composed of amino-acid chains arranged in a cross-beta pattern together with various sugars and other components such as serum amyloid P. All these cross-beta type structures exhibit apple-green birefringence under the microscope when stained with Congo red and viewed under polarised light.

The first reported case of what came to be known as amyloid was published in 1639, when large white stones were discovered in the spleen of a young man at autopsy. In 1828 John Abercrombie, physician to the king in Scotland, and his colleagues at the Edinburgh School were the first to describe the waxy appearance of the liver. The term ‘amyloid’ was coined in 1838 by the German botanist Matthias Schleiden to describe a normal amylaceous constituent in plants. It was adopted by the German pathologist Rudolf Virchow in 1860 to describe the pathological appearances in amyloidosis. Cardiac involvement, described as ‘weakness of the heart muscle’, has been recognised since the mid-1850s, while the association with myeloma was first recognised by Hermann Weber in 1867.

Until fairly recently, amyloidosis was classified as primary (often associated with underlying plasma cell dyscrasia), senile, familial and secondary (usually associated with various connective tissue and inflammatory bowel diseases). However, amyloidosis is now classified chemically, depending on the nature of the fibrillar protein. Twenty-three different fibrillar proteins have been described in human amyloidosis (Table 1).

Most cases of what previously was termed amyloid are associated with immunoglobulin light chain fibrillar proteins (AL amyloidosis). AL amyloidosis is a monoclonal plasma cell disorder closely related to multiple myeloma, and treatment mirrors the treatment of multiple myeloma. Similarly, those previously classified with ‘senile’ amyloid and many cases of familial amyloidosis are associated with the fibrils of transport protein transthyretin (TTR) and are now termed ATTR. Although familial amyloidosis rarely affects the heart, specific mutations in the transthyretin (ATTR) and apolipoprotein-AI (ApoAII) are associated with predominant cardiac involvement.

Reactive amyloidosis (AA amyloidosis) was formerly termed secondary amyloidosis and is the most common systemic amyloidosis worldwide. It is associated with chronic inflammation and occurs in various inflammatory, infective and neoplastic disorders. The precursor protein is a normal-sequence apo-SAA (serum amyloid A protein), which is an acute phase reactant that circulates bound to high-density lipoprotein.

In all forms of amyloidosis the cell secretes the precursor protein in a soluble form that becomes insoluble at some tissue site, compromising organ function. Many patients with amyloidosis have multi-system involvement at diagnosis. AL amyloidosis should be considered in any patient who presents with nephritic range proteinuria with or without renal insufficiency, non-dilated...
cardiomyopathy, peripheral neuropathy, hepatomegally or autonomic neuropathy. Initial investigation is aimed at confirming the diagnosis of amyloidosis by tissue biopsy with subsequent tests to establish the type and extent of the disease.

Biopsy of an affected organ is usually diagnostic, although less invasive alternatives, such as fat aspiration or rectal biopsy, should also be considered. Amyloid deposits classically produce red-green birefringence under polarised light when stained with Congo red.

Once the presence of amyloidosis has been confirmed, it is imperative that the amyloid type is established to plan appropriate treatment. Antibodies have been developed for most known amyloid proteins. Immunohistochemical staining of the biopsied tissue with a panel of amyloid protein antibodies is used to establish the nature of the underlying fibrillary protein. However, in AL amyloidosis results are often inconclusive due to background normal immunoglobulins. In situations where immunohistochemistry is inconclusive, DNA analysis or fibril protein sequencing can be used to obtain a definitive diagnosis.

As well as the type of amyloidosis, it is imperative to establish the extent of organ involvement. Generalised abnormalities of liver function are rare, although an elevated alkaline phosphatase is commonly found. The chest X-ray may show reticulo-nodular shadowing in pulmonary amyloidosis, and there may be impaired CO diffusion on pulmonary function tests. Serum amyloid P (SAP) scintigraphy is routinely performed in most individuals referred for assessment and is useful in assessing the distribution of organ involvement as well as the response to treatment. However, SAP scintigraphy is unable to image amyloid in the moving heart, and electrocardiograms (ECG) and echocardiograms are essential. Nerve conduction studies may be required where neuropathy is the predominant symptom, and nerve biopsy is occasionally required to establish the diagnosis. Poor prognostic factors at presentation are echocardiographic evidence of cardiac involvement, a large amyloid load on SAP scintigraphy, autonomic neuropathy, hyperbilirubinaemia and associated myeloma.

Cardiac amyloidosis is characterised by the infiltration of extracellular amyloid protein throughout the myocardium, valves and perivascular tissues. This may result in restrictive cardiomyopathy, coronary insufficiency producing chest pain or myocardial infarction, valvular dysfunction, atrial thrombus or cardiac arrhythmias. ECG changes may include small voltage QRS complexes, first-degree heart block and non-specific ST segment changes. The degree of cardiac involvement varies with the type of amyloidosis. Senile amyloidosis (ATTR)

<table>
<thead>
<tr>
<th>Type</th>
<th>Fibril protein</th>
<th>Clinical setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic</td>
<td>Immunoglobulin light chains</td>
<td>Plasma cell dyscrasia</td>
</tr>
<tr>
<td></td>
<td>Transthyretin</td>
<td>Familial amyloidosis, senile amyloidosis</td>
</tr>
<tr>
<td></td>
<td>A amyloidosis</td>
<td>Inflammation-associated amyloidosis, familial Mediterranean fever</td>
</tr>
<tr>
<td></td>
<td>β2-microglobin</td>
<td>Dialysis-associated amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Immunoglobulin heavy chains</td>
<td>Systemic amyloidosis</td>
</tr>
<tr>
<td>Hereditary</td>
<td>Fibrinogen α chain</td>
<td>Familial systemic amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Apolipoprotein-AI</td>
<td>Familial systemic amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Apolipoprotein-AII</td>
<td>Familial systemic amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Lysozyme</td>
<td>Familial systemic amyloidosis</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>β protein precursor</td>
<td>Alzheimer’s syndrome, Down’s syndrome, hereditary cerebral haemorrhage with amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Prion protein</td>
<td>Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, fatal familial insomnia</td>
</tr>
<tr>
<td></td>
<td>Cystatin C</td>
<td>Hereditary cerebral haemorrhage with amyloidosis</td>
</tr>
<tr>
<td></td>
<td>ABri precursor protein</td>
<td>Familial dementia (British)</td>
</tr>
<tr>
<td></td>
<td>ADan protein</td>
<td>Familial dementia (Danish)</td>
</tr>
<tr>
<td>Ocular</td>
<td>Gelsolin</td>
<td>Familial amyloidosis (Finnish)</td>
</tr>
<tr>
<td></td>
<td>Lactoferrin</td>
<td>Familial corneal amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Keratoepithelin</td>
<td>Familial corneal dystrophies</td>
</tr>
<tr>
<td>Localised</td>
<td>Calcitonin</td>
<td>Medullary thyroid carcinoma</td>
</tr>
<tr>
<td></td>
<td>Amylin</td>
<td>Islet amyloid polypeptide amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Atrial natriuretic factor amyloidosis</td>
<td>Isolated atrial amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Prolactin</td>
<td>Pituitary amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Keratin</td>
<td>Cutaneous amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Medin</td>
<td>Aortic amyloidosis in elderly people</td>
</tr>
</tbody>
</table>

TABLE I Amyloidosis, associated fibrillary proteins and their clinical manifestations (reproduced from BA Baethge and DR Jacobson with permission from eMedicine)
individuals with cardiac amyloidosis usually present with dyspnoea, a common and non-specific symptom, and early cardiac investigations are often unhelpful or misleading.

This case series looks at the clinical presentation of seven patients for whom the final diagnosis was cardiac amyloidosis. We discuss some of the diagnostic difficulties encountered that contributed to a delay in diagnosis.

**Case 1**
A 70-year-old man presented with exertional dyspnoea and chest pain. He gave a two-year history of joint pains, lethargy and weight loss. The initial ECG showed sinus rhythm with first-degree heart block (Figure 1.1). His echocardiogram and chest X-ray were reported as normal. He went on to have a treadmill test, which was terminated early with widespread infero-lateral ST depression. A subsequent coronary angiogram demonstrated normal coronary arteries.

The patient's dyspnoea persisted, and he was therefore referred for a respiratory opinion. Pulmonary function tests revealed a mildly obstructive defect, and a repeat echocardiogram demonstrated a small pericardial effusion. No cause for his dyspnoea was identified, and he was referred for investigation of possible sleep apnoea.

A computerised tomography (CT) scan of the thorax, however, showed features of cardiac failure, which prompted us to repeat the cardiac investigations. By this stage, the ECG changes had progressed with a reduction in the QRS voltage in the limb leads, with loss of the R wave in the anterior chest leads (Figure 1.2). The

**FIGURE 1** ECGs from Case 1, a 70-year-old man who presented with exertional dyspnoea, chest pain and a two-year history of joint pains, lethargy and weight loss. An initial ECG showed sinus rhythm with first-degree heart block (1.1); a later ECG showed progression with a reduction in the QRS voltage in the limb leads with loss of the R wave in the anterior chest leads (1.2). A treadmill test was terminated early with widespread infero-lateral ST depression.

**FIGURE 2** Echocardiogram suggestive of an infiltrative process from Case 1, whose CT scan at this stage showed features of cardiac failure. A coronary angiogram was normal. 1: Parasternal short axis view demonstrating a concentric thickened left ventricle (A) with thickening of the mitral valve leaflets (B). A small pericardial effusion is also demonstrated (C). 2: Parasternal long axis view demonstrating thickening of the left ventricular posterior wall (A) and septum (B) with the typical speckling appearance seen in cardiac amyloidosis. A pericardial effusion is again visualised (C). 3: A four-chamber view demonstrating marked hypertrophy of the inter-ventricular septum (A) with enlargement of the left (B) and right (C) atria.
echocardiogram now suggested an infiltrative process (Figure 2). The patient was admitted for cardiac and rectal biopsy, which provided immunohistochemical confirmation of AL-type amyloidosis (Figure 3). He was later found to have an underlying lambda light chain secreting plasma cell dyscrasia with multiple lytic skull lesions. Bone marrow examination revealed >10% plasma cells. The patient was referred to a specialist centre for further management. He began chemotherapy but died of progressive cardiac failure two months after the diagnosis was made and 22 months after he first presented with symptoms of breathlessness.

Case 2

A 59-year-old woman presented to her GP with an 18-month history of worsening exertional dyspnoea. She smoked 20 cigarettes a day and consumed 50 units of alcohol per week. There was no history of chest pain, but she complained of ankle swelling and orthopnoea. Her chest X-ray showed an enlarged heart with mild pulmonary oedema, and a provisional diagnosis of alcohol-related cardiomyopathy was made.

At the cardiology outpatient review the patient was noted to have generalised bruising, a soreness in her mouth and numbness in her hands suggestive of bilateral carpal tunnel syndrome. The ECG showed sinus rhythm with small QRS complexes in the limb leads and Q waves across the anteroseptal leads. The echocardiogram showed a stiff left ventricle with mild left ventricular systolic impairment and severe left ventricular hypertrophy. Doppler filling showed a restrictive pattern. The initial suspicion was of cardiac amyloidosis, and admission was arranged for further investigation.

Rectal biopsy was performed. Congo red stain for amyloid confirmed apple-green birefringence around vessels in the lamina propria and muscularis mucosa consistent with systemic amyloidosis. Cardiac biopsy similarly confirmed the presence of amyloid within the myocardial fibres and deposited in the vessel walls. Immunoglobulins revealed an IgG lambda myeloma and lambda free light chain excess. The patient began chemotherapy, and her condition initially stabilised. However, she developed progressive cardiac failure and died 26 months after the initial diagnosis was made.

Case 3

A 76-year-old man was referred to cardiology outpatients with dyspnoea and exertional chest pain. There were no symptoms of cardiac failure. He had a history of hypertension and was taking bendroflumethiazide and aspirin. His ECG showed sinus rhythm with normal amplitude of the QRS complexes. His echocardiogram showed good left ventricular function and normal-sized chambers with moderate concentric left ventricular hypertrophy. He exercised for nine minutes before stopping due to breathlessness and inferior ST segment depression. He was diagnosed with angina and commenced on a long-acting nitrate. Eighteen
months later he developed congestive cardiac failure, and a further echocardiogram suggested cardiac amyloidosis. His clinical condition deteriorated before a tissue diagnosis could be made. Post-mortem examination confirmed the presence of amorphous eosinophilic material disrupting the cardiac muscle fibres. These showed apple-green birefringence under polarised light, confirming the diagnosis of cardiac amyloidosis.

**Case 4**

A 53-year-old woman was referred to general medicine outpatients with a 12-month history of exertional chest pain. Her initial ECG showed inferior ST segment flattening, which worsened during exercise testing in association with chest tightness. Coronary arteriography showed normal coronaries. She was reassured and discharged from follow-up.

Two years later the woman was re-referred with exertional chest pain and dyspnoea. Her ECG at this stage was very abnormal, with left axis deviation and widespread lateral ST depression. The echocardiogram showed moderate left ventricular systolic impairment with asymmetric left ventricular hypertrophy. A provisional diagnosis of hypertrophic cardiomyopathy was made. Cardiac magnetic resonance imaging (MRI) showed gross free wall and septal hypertrophy, with obliteration of the left ventricle cavity in systole.

The patient’s symptoms progressed over the next three months – she reported weight loss, constipation and general lethargy and developed pleural effusions. Her ECG by now showed low voltage complexes in comparison with previous recordings, with a pseudo-infarct pattern in her anterior leads. Further tests revealed an abnormal liver function and an IgG lambda paraprotein band. However, rectal biopsy was negative for amyloid. Bone marrow examination showed a plasma cell population and cardiac biopsy later demonstrated AL amyloidosis.

She was referred to the National Amyloidosis Centre in London but died from progressive cardiac failure before commencing chemotherapy, only six weeks after diagnosis.

**Case 5**

A 70-year-old woman presented with exertional chest pain and wheeze. Her ECG showed first-degree heart block and incomplete left bundle branch block. Blood tests and chest X-ray were normal. A treadmill test was terminated after 2½ minutes due to dyspnoea and slight ST depression in her inferior leads. Pulmonary function tests showed normal lung volumes with evidence of moderate airflow obstruction. The airflow obstruction was shown to improve with inhaled salbutamol. Her echocardiogram showed good left ventricular systolic function with asymmetrical hypertrophy at the interventricular septum. She was treated with inhalers for late-onset asthma.

Two years later the patient presented with atrial fibrillation. This was associated with a fast ventricular rate. Her echocardiogram again showed normal systolic function. Over the next six months her symptoms progressed with worsening dyspnoea, exertional chest pain and reduced exercise tolerance. She had further admissions with pulmonary oedema and repeated echocardiograms, all demonstrating left ventricular hypertrophy and good systolic function – out of keeping with her clinical symptoms. A thallium scan showed homogenous myocardial perfusion.

The patient was referred to our tertiary centre for further investigation. Her echocardiogram showed left ventricular hypertrophy with good systolic function, biaatrial enlargement and mild mitral regurgitation. An initial diagnosis of hypertrophic cardiomyopathy was made. Symptoms progressed quickly over several months: she complained of weight loss, poor appetite and constipation. At this stage there was visible macroglossia and periorbital oedema (both strongly suggestive of AL amyloidosis) as well as parotid gland enlargement. Kussmaul’s sign (a rise in the jugular venous pressure on inspiration) was positive, indicating a probable restrictive cardiomyopathy. Rectal biopsies confirmed AL amyloidosis.

The patient was referred to the National Amyloidosis Centre for assessment. After discussion she opted for treatment with a combination of oral thalidomide and
<table>
<thead>
<tr>
<th>Patient</th>
<th>Presenting symptoms</th>
<th>ECG</th>
<th>CXR</th>
<th>Initial diagnosis</th>
<th>time to diagnosis</th>
<th>Underlying cause</th>
<th>Serum creatinine (at diagnosis, µmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>SOB, exertional CP</td>
<td>30 sec depression at 2 min, no ST depression</td>
<td>Cardiomegaly, bilateral pleural effusions</td>
<td>Myeloma, AL amyloidosis</td>
<td>17 months</td>
<td>Myeloma, AL amyloidosis</td>
<td>114</td>
</tr>
<tr>
<td>2</td>
<td>SOB at rest, exertional CP</td>
<td>9 min ST depression 5 min after</td>
<td>Cardiomegaly, pulmonary oedema</td>
<td>Myeloma, AL amyloidosis</td>
<td>6 months</td>
<td>Myeloma, AL amyloidosis</td>
<td>118</td>
</tr>
<tr>
<td>3</td>
<td>Lower limb weakness, breathlessness, dyspnoea</td>
<td>No perf. at 2 min</td>
<td>Normal</td>
<td>Amyloidosis (post-mortem diagnosis)</td>
<td>12 months</td>
<td>Amyloidosis (post-mortem diagnosis)</td>
<td>70</td>
</tr>
<tr>
<td>4</td>
<td>Exertional chest pain, dyspnoea</td>
<td>Normal</td>
<td>Cardiomegaly</td>
<td>AL amyloidosis, lambda secreting plasma cell dyscrasia</td>
<td>18 months</td>
<td>AL amyloidosis, lambda secreting plasma cell dyscrasia</td>
<td>112</td>
</tr>
<tr>
<td>5</td>
<td>Moderate systolic dysfunction, restrictive mitral inflow pattern</td>
<td>2,221 pmol/L</td>
<td>Cardiomegaly</td>
<td>Amyloidosis (post-mortem diagnosis)</td>
<td>27 months</td>
<td>Amyloidosis (post-mortem diagnosis)</td>
<td>112</td>
</tr>
<tr>
<td>6</td>
<td>Dypnoea, dizziness</td>
<td>Not performed</td>
<td>Cardiomegaly</td>
<td>ATTR amyloidosis</td>
<td>12 months</td>
<td>ATTR amyloidosis</td>
<td>112</td>
</tr>
<tr>
<td>7</td>
<td>Lower limb weakness, dyspnoea</td>
<td>Not performed</td>
<td>Cardiomegaly</td>
<td>Hypertensive heart disease</td>
<td>6 months</td>
<td>Hypertensive heart disease</td>
<td>112</td>
</tr>
</tbody>
</table>

**Table 4** Comparison of presenting features, diagnosis and investigations of seven patients.
cyclo-phosphamide. She initially appeared to progress well but subsequently developed progressive cardiac failure and died 14 months following diagnosis.

**Case 6**

A 70-year-old man presented with a 12-month history of progressive dyspnoea, fatigue and presyncopal episodes, six years after coronary bypass grafting. He had been investigated by his GP for weight loss and anaemia and had subsequently been referred to neurology with lower limb weakness. An initial diagnosis of motor neurone disease was made.

However, the patient's lower limb weakness progressed with bilateral sensory loss and generalised hyporeflexia more in keeping with a systemic illness. He was referred to cardiology outpatients because of orthostatic hypotension and cardiac failure. His ECG showed sinus rhythm with first-degree atrioventricular (AV) block, left axis deviation and right bundle branch block. His echocardiogram demonstrated moderate generalised systolic dysfunction with a thick, echo-dense interatrial septum. The left atrium was enlarged with moderate mitral regurgitation, and tissue velocity imaging confirmed a restrictive pattern. The combination of autonomic symptoms and a restrictive cardiomyopathy raised the suspicion of amyloidosis. There were no paraprotein bands on plasma electrophoresis. A bone marrow trephine revealed an excess of plasma cells of uncertain significance. Amyloid deposits were confirmed on both rectal and cardiac biopsy. Subsequent immuno-histochemistry confirmed systemic transthyretin-related amyloidosis. Although frail and cachectic at the time of presentation, the patient responded well to chemotherapy and his condition remained stable 22 months after the initial presentation.

**Case 7**

A 66-year-old woman presented acutely with progressive dyspnoea and dizziness. Her chest X-ray showed cardiomegaly and pulmonary oedema. Her ECG showed small inferior complexes with poor R-wave progression anteriorly. Cardiac enzymes were within normal limits. Her ECG remained unchanged, with small voltage complexes. The repeat echocardiogram showed concentric left ventricular hypertrophy (LVH) with moderately impaired systolic function and moderate mitral and tricuspid regurgitation. Her liver function was also now deranged. After further cardiology review, a clinical diagnosis of amyloidosis was considered in view of macroglossia and signs of restrictive cardiomyopathy. Her condition deteriorated and she died from multi-organ failure before a tissue diagnosis could be made. Post-mortem examination confirmed widespread AL amyloid disease.

**DISCUSSION**

This case series illustrates the various presentations of cardiac amyloidosis. The diagnosis of a multi-system disease is not easy; however, in retrospect the clinical clues are often present at an early stage. Interpretation of basic cardiac investigations should be performed in the context of a thorough history and careful clinical examination. The presence of advanced heart failure without any clearly identifiable pathology should alert the suspicious clinician, and discrepancies between investigations and clinical signs should provide an early warning.

The management of cardiac amyloidosis is two-fold, involving treatment of heart failure alongside treatment of the underlying amyloid process. Diuretic treatment is the mainstay of heart failure treatment. Angiotensin-converting enzyme (ACE) inhibitors are poorly tolerated because of symptomatic hypotension. Digoxin is bound to amyloid fibrils resulting in increased susceptibility to drug toxicity. There have been reports of an increased incidence of sudden death in patients with cardiac amyloidosis treated with digoxin. Calcium channel blockers are also bound to amyloid fibrils and have been shown to worsen clinical heart failure in cardiac amyloidosis. Many individuals have highly symptomatic orthostatic hypotension for which α blockade with midodrine may be beneficial.

Treatment of the underlying amyloid process depends on the type of amyloidosis and requires unequivocal amyloid typing. This has been improved by the recent introduction of assays for the circulating amyloid precursor proteins SAA in AA amyloidosis and serum immunoglobulin free light chains in AL amyloidosis.

By targeting the clonal plasma cells producing the monoclonal immunoglobulin light chains with chemotherapy agents, amyloid formation can be halted, organ function is preserved and survival is improved in AL amyloidosis. Sensitive immunoassays for AL fibril precursor protein allow us to monitor an individual’s response to chemotherapy and tailor a regime appropriately. A sustained reduction in the concentration of aberrant monoclonal light chains by 50% is associated with improved survival. High-dose chemotherapy with peripheral autologous stem cell rescue has become increasingly popular but has a high treatment-associated mortality. However, many individuals with AL amyloidosis tolerate this aggressive chemotherapy poorly, and the presence of cardiac amyloidosis is associated with increased mortality.
and morbidity from peripheral stem cell transplantation.20,21 Those intolerant of high-dose chemotherapy may respond to intermediate-dose chemotherapy with vincristine, adriamycin and dexamethasone or melphalan and dexamethasone. Oral melphalan and prednisolone are better tolerated than more aggressive regimes, but many patients fail to respond.22

The treatment of the underlying inflammatory condition in AA amyloidosis that reduces the SAA concentration leads to improved survival.23 New agents that inhibit tumour necrosis factor and interleukin 1 suppress the acute phase response in many inflammatory conditions.24 In familial Mediterranean fever, colchicine largely prevents the development of AA amyloidosis. Eprodisate, a new class of agent that inhibits the polymerisation of amyloid fibrils and deposition of fibrils in the tissues, has recently shown promising results in slowing the decline in renal function in AA amyloidosis.25

Cardiac transplantation for cardiac amyloidosis is rarely performed because of concerns of amyloid deposition in the transplanted heart. Recently, sequential heart and stem cell transplants in young patients without renal, gastrointestinal or autonomic involvement have shown some promise.24,27

By reviewing patient records we have highlighted particular features in the history, examination and subsequent investigation that should prompt the clinician to consider the possibility of cardiac amyloidosis in patients with unexplained cardiac symptoms. In all of these cases progressive exertional dyspnoea was the main presenting symptom. Four patients gave a history of exertional chest pain – although not always typical of angina. Non-cardiac symptoms (Case 6) should also suggest the presence of a multi-system disease. Weight loss and lethargy (Case 1) are non-specific, but in the elderly patient should raise the possibility of myeloma, particularly in the context of anaemia. Weight loss is also a common feature of AL amyloidosis in the absence of underlying myeloma. Orthostatic hypotension and constipation suggest autonomic involvement; abdominal discomfort may suggest organomegaly. Periorbital purpura and macroglossia are frequently observed in systemic AL amyloidosis.

The characteristic signs of a restrictive cardiomyopathy are not easy to elicit. The jugular venous pressure (JVP) may be elevated and Kussmaul’s sign (JVP that rises paradoxically with inspiration) detected. The apex is usually palpable and undisplaced. Heart sounds may be distant with an audible S3 and S4. The restricted ventricular filling may result in peripheral oedema, ascites and hepatomegaly. Extra-cardiac manifestations are suggestive of a systemic illness. The presence of bruising, specifically periorbital purpura, and an enlarged tongue are pathognomonic of systemic amyloidosis (Case 2).

**ECG**

Although there are no diagnostic ECG findings in cardiac amyloidosis various non-specific abnormalities are common (Table 2). There is progressive reduction in the QRS amplitude with disease progression (which is accompanied by progressive thickening of the myocardium on imaging). The presence of low voltage (<0.5 mV) complexes in the limbs leads therefore provides a clue. This is often accompanied by marked axis deviation and first-degree heart block.28 Interestingly, most patients remain in sinus rhythm with normal QRS width – due to an unexplained tendency for amyloid fibrils to be deposited within the His-Purkinje system rather than the AV node.11 Non-specific ST changes often lead to the more common diagnosis of myocardial ischaemia.

**Exercise testing**

Exercise testing is a simple means of assessing exertional symptoms of a possible cardiac aetiology. Four of our patients underwent such a stress test. All of the individuals who underwent exercise testing developed non-specific ST changes suggestive of possible underlying coronary disease. Three of these individuals subsequently underwent coronary arteriography and were found to have normal coronary arteries. One patient had a normal myocardial perfusion scan. In all cases the original abnormality was not revisited but perhaps in retrospect should have indicated an underlying cardiomyopathy.

**Echocardiography**

The echocardiogram typically changes with disease progression (Table 3). Mean left ventricular wall thickness >12 mm, in the absence of hypertension or another cause of left ventricular hypertrophy, is very suggestive of amyloidosis.29 The presence of right ventricular wall thickening without pulmonary pathology and thickening of the valves and interatrial septum further strengthen this argument.30 Doppler studies generally reveal a degree of diastolic dysfunction,31 while tissue Doppler imaging indicates that peak early diastolic wall motion velocity is decreased in most walls before the onset of congestive heart failure.32 However, diastolic dysfunction is a common finding in the elderly population and often disregarded – or its relevance misunderstood by the general physician. A reduction in ejection fraction and systolic dysfunction are usually late signs.33 The Tei index (defined as the sum of the isovolumetric contraction time and isovolumetric relaxation time divided by the ejection time) gives a combined index of systolic and diastolic myocardial performance, and has been shown to relate to clinical outcomes in cardiac amyloidosis.34 Typically the Doppler-derived isovolumetric contraction and relaxation times are prolonged with shortening of the ejection time. It is the combination of low-voltage or pseudo-infarct patterns on the ECG, and increased myocardial thickness with speckling on the echocardiogram, which is specific for cardiac amyloidosis.35
MRI

Several studies indicate that cardiac MRI has a role in discriminating between hypertrophic and restrictive cardiomyopathy. The presence of late gadolinium enhancement is said to be a characteristic feature of cardiac amyloidosis. The sensitivity of this is, at present, unclear. However, in the future it may have a role to play in improving non-invasive surveillance in patients with known systemic amyloidosis. To date there have been no large studies directly comparing MRI with echocardiography in the diagnosis of cardiac amyloidosis.

Serum amyloid P scintigraphy

Radiolabelled serum amyloid P component scintigraphy is a simple, reproducible method of quantifying the uptake of 123I-labelled serum amyloid into various organs. It is diagnostic of amyloid in most patients with AA and AL amyloidosis and fewer with ATTR-type amyloidosis. Although it often reveals more widespread organ involvement than is identified clinically, it is not useful in the evaluation of cardiac amyloidosis.

NT-ProBNP

Elevation of the N-terminal pro-brain natriuretic peptide (NT-proBNP) is associated with many cardiac conditions. Very high levels are consistent with cardiac amyloidosis and related to increased mortality. NT-proBNP has been studied mainly in AL amyloidosis. The most important cause of NT-proBNP elevation in AL amyloidosis is a direct toxic effect of the circulating amyloidogenic light chain, beside ventricular filling pressure and amyloid infiltration. There are suggestions that patients with a hereditary form of amyloidosis (ATTR amyloidosis) affecting the heart have lower levels of NT-proBNP. No patient with cardiac involvement has a normal NT-proBNP, and this is of help in defining the presence of heart involvement in patients who do not have a clear-cut echocardiographic pattern. Serial measurement of NT-proBNP during chemotherapy in AL amyloidosis suggests that cardiac function can improve rapidly despite echocardiographic appearances remaining unchanged.

Troponin

Cardiac troponins T and I are highly sensitive and specific biomarkers of myocardial injury. In cardiac amyloidosis, amyloid deposition in the coronary microvasculature and myocyte compression from amyloid infiltration is thought to account for the observed troponin elevations. For patients newly diagnosed with AL amyloidosis, the median survival is worse for those in whom the troponin is elevated.

Together, NT-proBNP and cardiac troponins are powerful prognostic determinants in AL amyloidosis and have been suggested as a method for staging the disease.

Tissue diagnosis

The definitive diagnosis of amyloidosis requires a tissue biopsy demonstrating the classical apple-green birefringence with Congo red stain when viewed under a polarised microscope. In the presence of typical echocardiographic appearances, endomyocardial biopsy is not necessary providing a histological diagnosis has been made from another tissue. Abdominal fat fine-needle aspiration is positive for amyloid in more than 70% of patients with AL amyloidosis. However, if clinical suspicion remains high despite negative peripheral biopsy, endomyocardial biopsy is indicated. In the correct hands this a safe and simple procedure with a high sensitivity as amyloid is deposited widely through the cardiac tissues.

In this case series several patients (Cases 1, 3 and 6) had cardiac biopsies when tissue diagnosis had already been made, putting patients at unnecessary risk.

As mistyping of amyloidosis can lead to therapeutic mistakes, accurate tissue typing is required. Light microscopy immunohistochemistry has a low specificity, particularly in AL amyloidosis, and should be used with great caution for typing. It can also result in false positive results due to serum proteins detected in the tissues which are not related to amyloid, or false negatives due to cleavage products of the amyloid fibrils losing their epitopes or having a different structure to their precursor proteins. Immunoelectron microscopy can be used to distinguish contaminated labelled protein structures and can detect amyloid when histochemical stains such as Congo red are still negative.

Making the diagnosis

In uncommon multi-system disorders such as amyloidosis, it is only clinical suspicion that allows early diagnosis. Breathlessness without left ventricular systolic dysfunction all too often leads us towards a respiratory diagnosis. However, signs or symptoms of heart failure in individuals with normal left ventricular systolic function may indicate an infiltrative process. Marked ventricular hypertrophy on the echocardiogram in the presence of small QRS complexes should similarly point to the possibility of amyloidosis (Case 7). Likewise, a strongly positive exercise test with normal coronary arteries should raise suspicion of heart muscle disease (Case 1). It is vital that abnormal cardiac investigations are carefully interpreted within their clinical context.

CONCLUSION

Symptoms and signs of heart failure with preserved left ventricular systolic function in the early stages of presentation are a common theme in this case series. Later, with disease progression, clinical and echocardiographic features of restrictive left ventricular filling pattern and low voltage complexes on the ECG emerge as more specific findings.
Definitive diagnosis of amyloidosis requires a tissue biopsy. Cardiac biopsy is not always necessary, providing a histological diagnosis can be made from other tissues with typical features on echocardiography supporting cardiac involvement. Magnetic resonance imaging and measurement of NT-proBNP may be helpful adjuncts to our assessment in the future.

Cardiac amyloidosis is a progressive disabling disease with a poor prognosis. Our experience over a 12-month period has emphasised the importance of reviewing previous investigations and comparing current clinical status and ECG with previous records. Uncommon disorders such as amyloidosis require a systematic approach and clinical awareness to enable early diagnosis and therapy.

REFERENCES


---

**UPCOMING EDITORIAL VACANCIES AT THE JOURNAL**

**Editor and Clinical Section Editor**

*The Journal of the Royal College of Physicians of Edinburgh*

Expressions of interest are invited for the above posts from Fellows. Both positions are honorary and will become available in March 2009, with a handover period until June 2009. Support is provided by an experienced production staff of three within the College.

The *Journal* is a quarterly 96-page publication consisting of three sections – Clinical, Education and History. It has a circulation of about 8,000, including all Fellows and Collegiate Members and some postgraduate libraries.

The **Editor** is responsible for the strategic direction of the *Journal* and for planning each issue. He or she works together with the three Section Editors to ensure high scientific and editorial standards and that work is carried out in accordance with editorial policies and good publishing practices. He or she is also responsible for commissioning editorials and clinical opinions, as well as arranging replies to letters to the Editor. The Editor reports to Council and has final editorial control over what goes into the *Journal*.

The **Clinical Section Editor** is responsible for refereeing, revising/editing and selecting submitted papers, and occasionally commissioning papers, for the Clinical section of the *Journal* (approx. 40 pages per quarter), ensuring a high standard and adequate flow of papers. He or she is also responsible for the editing of symposium reports and abstracts, and represents the *Journal* on the Symposium Committee.

Applicants for both posts will require good communication skills, a knowledge of the writing and editing of scientific articles and sufficient time to deal promptly with editorial decisions.

For further information, please contact:

Graeme McAlister, Head of Fellowship and Membership Services, Royal College of Physicians of Edinburgh, 9 Queen Street, Edinburgh EH2 1JQ, UK

Tel: +44 (0)131 247 3693
Email: g.mcalister@rcpe.ac.uk

Full job descriptions are available online at: www.rcpe.ac.uk (under ‘What’s new’)

Closing date: 2 November 2008